More recently, in an effort to improve upon the standard of care regimen using TMZ, a phase 3 trial was performed comparing the combination of lomustine and TMZ vs. standard TMZ in patients with newly diagnosed glioblastoma with methylated MGMT promoter, with a median survival of 31.4 m vs. 48.1m (88). Here, MGMT is linked to glioblastoma.